Posted by & filed under Governments & Regulators, Growth & Valuation, Management Issues, Personal Finance.

Description: Years of costly treatments could give way to pricier one-shot cures like Spark Therapeutics’ blindness drug. But insurers aren’t ready.


Date: April 06 , 2017


Questions for Discussions:

  • Summarize the various pricing models presented in this report.
  • What are the ethical and social considerations involved?
  • How should the players decide on pricing in this industry?
  • How should investors approach this discussion?

Leave a Reply

Your email address will not be published. Required fields are marked *